Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.

Abstract

We examined the effects of an inhibitor of 5-lipoxygenase (A-64077) in 11 patients with mild to moderately active ulcerative colitis (UC). Treatment was a daily oral dose of 800 mg for 28 days. Physicians global rating (scale 1-50) included stool characteristics, rectal bleeding, abdominal and rectal pain, urgency, and general well being; sigmoidoscopic evaluation (scale 1-15) included mucosal vascular pattern, erythema, granularity/ulcerations, friability, and exudate. All of the patients experienced a decrease in discomfort of their disease, and the gross appearance in the sigmoidoscopy improved in eight of them, but were not accompanied by histologic improvement. No significant side effects occurred. A long-term controlled double-blind and dose-effect trial using 5-lipoxygenase inhibitors is needed which may lead to a new therapeutic approach in UC.

• Authors: C Collawn, P Rubin, N Perez, J Bobadilla, G Cabrera, E Reyes, J Borovoy, D Kershenobich
• Journal: The American journal of gastroenterology (Am J Gastroenterol) Vol. 87 Issue 3 Pg. 342-6 (Mar 1992) ISSN: 0002-9270 [Print] United States
• PMID: 1539569 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Lipoxygenase Inhibitors
• zileuton
• Hydroxyurea

Topics

• Administration, Oral
• Adult
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Colitis, Ulcerative (drug therapy, pathology)
• Drug Evaluation
• Female
• Humans
• Hydroxyurea (analogs & derivatives, therapeutic use)
• Lipoxygenase Inhibitors (therapeutic use)
• Male
• Sigmoidoscopy